Cobicistat

• UNSPSC Description:

  Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC50s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer?which increases the overall absorption of several HIV medications.

• Target Antigen:

  Cytochrome P450; HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Cobicistat.html

• Purity:

  99.77

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  CN(C(N[C@@H](CCN1CCOCC1)C(N[C@@H](CC2=CC=CC=C2)CC[C@@H](NC(OCC3=CN=CS3)=O)CC4=CC=CC=C4)=O)=O)CC5=CSC(C(C)C)=N5

• Molecular Weight:

  776.02

• References & Citations:

  [1]Lianhong Xu, et al. Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. ACS Med. Chem. Lett., 2010, 1 (5), pp 209–213|[2]Temesgen Z. Cobicistat, a pharmacoenhancer for HIV treatments. Drugs Today (Barc). 2013 Apr;49(4):233-7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  1004316-88-4